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clotted serum is attributed to the generation of thrombin (a 
serine protease in its activated form) in the coagulation pro-
cess. The blood group specificity of the antibodies involved 
in this phenomenon is usually undetermined. There have 
been three instances in which antibodies reacting in serum 
but not in plasma have been determined to have blood 
group specificities, and they are autoanti-Sc1,4 autoanti-
Kpb,5 and autoanti-c.6 Ulcerative colitis is also associated 
with a positive DAT as a result of warm autoantibodies. The 
association of a positive DAT with ulcerative colitis was first 
described by Lorber et al. in 1955.7 Autoimmune hemolytic 
anemia (AIHA) is an infrequent but serious complication 
of ulcerative colitis with a reported frequency of 0.7 per-
cent.8 The prevalence of a positive DAT in ulcerative colitis 
patients without progression to AIHA is unknown. To our 
knowledge, we report the first case in which both the phe-
nomenon of IgG-RBC sensitization associated with serine 
proteases and a warm autoantibody are present concur-
rently in a pediatric patient with ulcerative colitis.
 
Case Report
 The patient is a 14-year-old Hispanic girl who initially 
presented in August 2006 at the age of 12 with an 8-month 
history of bloody stools, abdominal pain, and weight loss. 
She was hospitalized and a clinical workup was initiated. 
On physical examination she was pale and lethargic. Abnor-
mal laboratory findings included a Hb of 4.0 g/dL (normal 
range, 11.5–16 g/dL); Hct, 13.4% (37–47%); MCV, 54.4 fL 
(80–96 fL); MCH, 16.4 pg (27–32 pg); MCHC, 30.2 g/dL 
(32–36 g/dL); erythrocyte sedimentation rate, 35 mm/h 
(0–20 mm/h); reticulocyte count, 3.2% (0.5–1.5%); LDH, 
233 U/L (105–333 U/L ); bilirubin, 0.7 mg/dL (0.3–1.9 
mg/dL); C-reactive protein, 1.61 mg/dL (1.0–3.0 mg/dL); 
positive anti-cardiolipin antibodies (negative); ferritin < 2 
ng/mL (7–140 ng/mL); iron, 9 μg/dL (50–170 μg/dL); al-
kaline phosphatase, 54 IU/L (20–140 IU/L); and positive 
atypical perinuclear antineutrophil cytoplasmic antibodies 
(P-ANCA) with a titer of 1:1280 (negative). Stool culture 
for Clostridium difficile toxin was positive. Other labora-
tory findings included a WBC of 6.9 × 103/μL (4.8–10.8 × 
103/μL) with a differential of 25% segmented neutrophils, 
28% bands, 30% lymphocytes, 13% monocytes, 2% eosino-
phils, and 2% atypical lymphocytes. Platelet count was 344 
× 109/L (150–450 × 109/L); prothrombin time, 15.3 sec-
onds (< 10–15 seconds); activated partial thromboplastin 
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Background
In 1980, Garratty and colleagues
1 described and inves-
tigated an unusual phenomenon in which a patient’s 
blood had a positive DAT in clotted samples but a nega-
tive DAT in anticoagulated samples. Since it was first recog-
nized, there have been several theories put forward to ex-
plain this phenomenon. The current prevailing hypothesis 
used to explain the phenomenon is one proposed by Garrat-
ty in 1993.2 Garratty suggested that the observed phenom-
enon was attributable to IgG-RBC sensitization associated 
with serine proteases. In 1993, Garratty performed a re-
view of case reports for patients with this phenomenon. He 
found that 71 percent of patients had a history of ulcerative 
colitis or other inflammatory bowel diseases.2 The proposed 
mechanism for the phenomenon of IgG-RBC sensitization 
associated with serine proteases is that an antibody in the 
patient’s serum is directed against an epitope present on 
most serine proteases.3 Theoretically, the generated com-
plexes would then bind to RBCs. The reactivity observed in 
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time, 28.9 seconds (< 35 seconds); INR, 1.20 (0.8–1.2); 
and fibrinogen, 395 mg/dL (200–400 mg/dL). A CT scan 
of her abdomen showed inflammation of the entire colon. 
No abnormalities of the small bowel were seen on an up-
per gastrointestinal series. She underwent a colonoscopy, 
which showed inflammation and friability of the mucosa. 
Colonic biopsies showed cryptitis and crypt abscesses to 
the hepatic flexure. The colonoscopic findings in conjunc-
tion with her elevated atypical P-ANCA laboratory findings 
confirmed a diagnosis of ulcerative colitis. She was treated 
with intravenous methylprednisolone, oral mesalamine, 
metronidazole, and 6-mercaptopurine.  The patient had no 
signs or symptoms of AIHA and this was not considered 
as a cause of her anemia.  The patient did have significant 
GI bleeding, which her treating physician determined to be 
the cause of her anemia. During this hospitalization, she 
received 4 units of packed RBCs to correct 
her anemia. During the next year she re-
quired several courses of steroids and she 
was started on infliximab (Remicade) ap-
proximately 14 months after her initial di-
agnosis. She was observed to develop hives 
that worsened on subsequent dosing. The 
infliximab therapy was discontinued and 
adalimumab (Humira) was instituted.
 In February 2008, when the patient 
was 14 years old, she was found to have a 
Hb of 6.9 g/dL on routine monthly blood 
work. She was subsequently admitted to 
the hospital for further workup and evaluation. Initial se-
rologic evaluation showed a positive DAT. Serum reactiv-
ity also was detected with all RBCs tested at antiglobulin 
phase using standard tube technique. The serologic evalu-
ation was unable to be completed by the hospital, and the 
samples were sent to the immunohematology reference 
laboratory (American Red Cross, West Henrietta, NY) for 
evaluation of a positive DAT and antibody identification.
Immunohematologic Evaluation and Results
 The results of initial pretransfusion testing showed 
an ABO discrepancy between the forward typing and the 
reverse grouping when testing the patient’s RBCs and se-
rum using standard tube technique according to manu-
facturer’s instructions. The patient’s RBCs forward typed 
as group A and the Rh type was D+. Test results obtained 
with the reverse-grouping cells were inconclusive owing to 





, B, O cells; Referencells, Immucor, Inc., Norcross, GA). 
Pretransfusion testing using RBCs from an EDTA sample 
showed a positive DAT, reactive with both anti-IgG and 
anti-C
3
 (Immucor, Inc.). DAT testing was not performed 
on RBCs from a clotted sample as our reference laboratory 
does not routinely perform DAT testing on such samples. 
A cold autoagglutinin was initially thought to be present 
on the patient’s RBCs because of the additional reactivity 
detected with all reverse-grouping cells tested. The positive 
DAT result obtained with anti-C
3
 could also be attribut-
able to the presence of a cold autoagglutinin. To determine 
whether a cold autoagglutinin was indeed present, the pa-
tient’s serum was treated with 0.01 M DTT (Sigma-Aldrich, 
St. Louis, MO) to abolish IgM activity. No change in reac-
tivity was noted when the patient’s DTT-treated serum was 
tested against the reverse-grouping cells. The patient’s neat 
serum and reverse-grouping cells were then warmed to 37°C 
before being added to the appropriately labeled test tubes. 
The test tubes were incubated at 37°C for 1 hour before be-
ing examined for agglutination. Using the prewarmed pa-
tient serum and reverse-grouping cells, there was no change 
noted in reactivity when retested; as such the presence of a 
cold autoagglutinin was excluded. The results obtained us-
ing these testing methods are shown in Table 1.
IgG-RBC sensitization associated with serine proteases
 An additional patient sample was requested to confirm 
that the discrepant reactivity was in fact sample related and 
not attributable to a sample tube mix-up. The reactivity de-
tected with the additional sample was identical to that of 
the original sample submitted, excluding the possibility of a 
sample tube mix-up.
 Owing to the initial reactivity detected with the reverse-
grouping cells, a selected cell panel was tested in a saline 
tube at 22°C to determine whether the reactivity was at-
tributable to an IgM antibody. No antibody reactivity, how-
ever, was detected when this testing was performed using 
the patient’s plasma. The same selected cell panel was then 
retested using the patient’s serum, and all cells were noted 
to be 4+ reactive. Because discrepant reactivity was detect-
ed between the patient’s serum and plasma, the patient’s 
plasma was tested against the reverse-grouping cells, and 
no ABO discrepancy was detected. Using this method, the 
patient’s blood type was determined to be A positive, which 
was consistent with the submitting hospital’s historical re-
cords.
 During the process of evaluating the serum versus plas-
ma discrepancy, the possibility of IgG-RBC sensitization as-
sociated with serine proteases was considered. To further 
evaluate this hypothesis, the patient’s plasma was clotted 
using thrombin (Sigma-Aldrich) to convert the plasma to 
serum. The plasma was initially nonreactive when tested 
against the group O reverse-grouping cells. Using the same 
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serum
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group O reverse-grouping cells, the converted serum was 
found to be 2+ reactive (see Table 2 for the test results ob-
tained using the patient’s plasma).
  As stated earlier, there have been three instances in 
which antibodies reacting in serum but not in plasma have 
been determined to have blood group specificities.4–6 The 
patient’s RBCs tested positive for the Sc1 antigen; however, 
Sc1-negative RBCs were 4+ reactive when tested against 
the patient’s serum in Micro Typing System (MTS) IgG gel 
(Ortho-Clinical Diagnostics, Raritan, NJ), thus excluding 
a possible IgG autoantibody with anti-Sc1 specificity. Au-
toanti-c was excluded based on the patient’s phenotype; the 
patient’s RBCs tested negative for the c antigen. Autoanti-
Kpb was not evaluated as this possibility was not known at 
the time of testing and was later identified during a further 
literature search after the completion of this workup.5
 Because the patient’s plasma was nonreactive when 
tested in a saline tube at 22°C, antiglobulin testing was 
performed using the patient’s plasma. Initial testing was 
performed in both MTS IgG gel and LISS-AHG (Immucor, 
Inc.). The patient’s plasma was 3+s reactive in both MTS 
IgG gel and LISS-AHG with three of three screening cells 
(Surgiscreen; Ortho-Clinical Diagnostics, Inc.) and two 
phenotypically similar cells. Autologous cells treated 
with EDTA-glycine acid (EGA) (Immucor, Inc.) to remove 
the IgG coating were also 3+ reactive. The patient’s serum 
was also tested and found to be 4+ reactive with the same 
two phenotypically similar cells when tested in MTS IgG 
gel.
 The pattern of reactivity detected when testing the pa-
tient’s plasma suggested the presence of an IgG autoanti-
body. We were unable to determine whether the reactivity 
detected when testing the serum sample at antiglobulin 
phase was also attributable to a possible IgG autoantibody 
or interference of the serine protease antibody. A 3× alload-





K– Jk(b–), glutaraldehyde-treated RBC to remove the IgG 
autoantibody reactivity and assess for the presence of un-
derlying alloantibodies. No underlying alloantibodies were 
detected when testing the 3× alloadsorbed plasma in LISS-
AHG. Alloantibodies to the major blood group antigens 
were ruled out by this testing.  An IgG autoantibody was 
concluded to be in the patient’s plasma because of:
Patient’s positive DAT, with anti-IgG, detected using 1. 
tube technique
Positive autocontrol, which consisted of the patient’s 2. 
RBCs treated to DAT negative tested against the pa-
tient’s plasma in LISS-AHG
 On February 14, 2008, the patient had a pretransfu-
sion Hb of 6.9 g/dL and was transfused with 2 units of 
least-incompatible packed RBCs, attaining a posttransfu-
sion Hb of 10.2 g/dL. There was no clinical or serologic evi-
dence of an adverse reaction after transfusion.
Discussion  
 This report describes the presence of the phenomenon 
of IgG-RBC sensitization associated with serine proteases 
in a patient with ulcerative colitis. In this case, a positive 
DAT owing to the presence of a warm autoantibody was 
also present. To our knowledge this is the first published 
case in which both entities are concurrently present in a 
patient. Both of these entities may have a respec-
tive association with ulcerative colitis. In this case, 
the antibodies involved in both the phenomenon of 
IgG-RBC sensitization associated with serine pro-
teases and the presence of a warm autoantibody 
were of the IgG class. The mechanism of the phe-
nomenon of IgG-RBC sensitization associated with 
serine proteases is not completely understood. The 
initial hypothesis proposed for the phenomenon 
was that the patient had an IgG antibody to an acti-
vated coagulation factor that would not normally be pres-
ent in plasma and that IgG immune complexes formed and 
attached to RBCs in vitro.1 In 1993, Garratty,2 performed 
a review of 28 patients with ulcerative colitis who mani-
fested the IgG-RBC sensitization phenomenon associated 
with in vitro clotting as initially reported in 1980. In this 
review, the author observed that 10 of 11 IgG antibodies 
tested were of the IgG3 subclass. Further, the author found 
that the IgG-RBC sensitization phenomenon was not di-
rectly related to clotting. Garratty observed that a nonreac-
tive plasma could be made reactive without clotting occur-
ring by adding a variety of serine proteases (e.g., trypsin) 
to the plasma. Therefore the hypothesis was subsequently 
modified to suggest that the antibody in the patient’s se-
rum was directed against an epitope present on most serine 
proteases. This would include but would not be restricted 
to activated coagulation factors.3
 In humans there are four broad classes of proteases, 
based on the mechanism they use to hydrolyze peptide 
bonds. Respectively, they are serine, cysteine, aspartic, and 
metalloproteases.9 Of these classes, the serine proteases are 
the largest group, and their functions range from those at-
tributable to nonspecific digestive enzymes such as trypsin, 
to more highly regulated functions such as blood coagula-
tion (thrombin) and immune response (complement sys-
tem). Nearly all serine proteases have amino acid sequence 
homology with pancreatic serine proteases. As a result, 
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IgG-RBC sensitization associated with serine proteases
serine proteases have very similar tertiary structures.10 The 
maintenance of structural homology within the serine pro-
tease class would be consistent with Garratty’s hypothesis 
regarding an antibody to an epitope commonly shared by 
serine proteases and his observation that a variety of serine 
proteases and not only those generated during the coagula-
tion process were capable of inducing the phenomenon of 
IgG-RBC sensitization associated with serine proteases.3
 Ulcerative colitis is a chronic inflammatory bowel dis-
ease that may be associated with extraintestinal immune 
features. Approximately 23 to 42 percent of patients with 
inflammatory bowel disease exhibit extraintestinal immu-
nologic manifestations.11 Immune hematologic features 
such as idiopathic thrombocytopenic purpura and AIHA 
have been reported in patients with ulcerative colitis.8,12 
Recently, the acquired form of thrombotic thrombocy-
topenic purpura (TTP) has also been described in patients 
with ulcerative colitis.13 The most favored hypothesis for the 
pathophysiology of acquired TTP is that of an autoimmune 
process caused by autoantibodies that inhibit the activity 
of the von Willebrand factor–cleaving metalloprotease AD-
AMTS13.14
 As the majority of the patients in whom the phenom-
enon of IgG-RBC sensitization associated with serine pro-
teases has been observed have a history of ulcerative colitis 
or other inflammatory bowel disease, the phenomenon of 
IgG-RBC associated with serine proteases may similarly 
reflect another autoimmune extraintestinal immunologic 
manifestation of inflammatory bowel disease. The autoim-
mune mechanism previously described in the pathogenesis 
of acquired TTP (autoantibody to a protease) would also be 
a plausible model for the phenomenon of IgG-RBC sensiti-
zation associated with serine proteases.
 A positive DAT in association with ulcerative colitis may 
occur as a result of the phenomenon of IgG-RBC sensitiza-
tion associated with serine proteases or may be attributable 
to a warm autoantibody with possible autoimmune hemo-
lytic anemia. The presence of both of these distinct entities 
in the same patient is a rare occurrence. Serologic investi-
gation of the phenomenon of IgG-RBC sensitization associ-
ated with serine proteases may be quite challenging, and in-
formation regarding the patient’s history of ulcerative colitis 
is beneficial. The clinical significance of the phenomenon of 
IgG-RBC sensitization associated with serine proteases is 
unknown. However, as best we are able to determine, it is 
not associated with accelerated RBC destruction in vivo. 
For those patients who have a positive serum and the phe-
nomenon of IgG-RBC sensitization associated with serine 
proteases is believed to be present, serologic testing may be 
repeated with plasma. If the plasma is subsequently nega-
tive then compatibility testing may be performed using the 
plasma as per the Standards of the American Association 
of Blood Banks, which allows plasma to be used for com-
patibility testing.3,15 Ulcerative colitis with a positive DAT 
and warm autoantibody is on rare occasion associated with 
hemolytic anemia and will require the appropriate transfu-
sion recommendations. In such cases, incompatible units 
screened negative for possible underlying alloantibodies 
will need to be selected, as crossmatch units will appear 
incompatible because of the presence of the IgG autoanti-
body. The patient will need to be monitored closely for signs 
and symptoms of hemolysis after transfusion. In summary, 
although the phenomenon of IgG-RBC sensitization associ-
ated with serine proteases does not appear to be associated 
with accelerated RBC destruction, it is important that this 
phenomenon be considered and recognized to avoid need-
less delay in serologic workup and the provision of blood for 
the patient.
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